Welcome to the November issue of The Pharmafile Brief, where we bring you the latest developments and conversations shaping healthcare, life sciences and pharma.
This issue also features an indepth look at a seldom discussed area of women’s health, Uterine Fibroids and the Cost of Silence, as Tina Backhouse from Theramex, reveals how the underdiagnosis and underfunding of fibroid research reflect wider gender health gaps and why advocacy and investment in women’s health innovation are long overdue.
Tina Backhouse
In our Visions4Health series, Sabina Syed looks at the ethics and implications of scientific innovation. Her article, Is this an Oppenheimer Moment for the Life Sciences Industry? discusses how biotech progress mirrors the dual-use dilemmas faced by physicists in the 20th century, asking what responsibility the sector has as AI, gene editing and personalised medicine accelerate at unprecedented speed.
Sabina Syed
In partnership with Visions4Health, the article, Turning a 10-Year Vision into a 10-Year Plan, reviews how policy, leadership and population health management are aligning to deliver the government’s ‘From sickness to prevention’ initiative.
In recognition of the Movember campaign and the growing awareness around mental well-being in healthcare, our Five Facts feature explores the state of men’s mental health today, from rising suicide rates to the stigma that still prevails, and considers what the industry can do to foster change.
In our regular Q&A feature, the Pharma Files, Dr Ewen Cameron, CEO of West Suffolk NHS Foundation Trust, shares his proudest achievements, the biggest challenge he has faced and what he is most excited about.
Dr Ewen Cameron
In this month’s news round-up, Pierre Fabre has partnered with the Know Your Lemons Foundation to advance breast cancer awareness, while Micrima prepares to launch a new UK-based breast cancer assessment system. Esaote unveiled an MRI innovation designed to support brain glioma surgeries and Alto Neurosciences has received FDA Fast Track designation for its new schizophrenia treatment.
There have been several key C-suite appointments across the industry this month: PolyNovo welcomed Bruce Peatey as CEO; Julius Clinical appointed Bassem Saleh as CEO, and FairJourney Biologics named Dr Werner Lanthaler as its new CEO. Also, Symeres named Gabriella Gentile as COO, strengthening its leadership team ahead of the company’s next phase of growth.
We hope you enjoy reading this issue of The Pharmafile Brief – look out for our next issue in December!
